Abstracts tagged "Bortezomib"

Abstract Number: 97 • 2017 Pediatric Rheumatology Symposium
Bortezomib is Efficacious in the Treatment of Refractory Neuropsychiatric SLE with Psychosis
Renee F Modica¹, Kathleen M Vazzana², Natalie Jane Shiff³, Akaluck Thatayatikom³ and Melissa E Elder¹, ¹Department of Pediatrics, University of Florida, Gainesville, FL, ²Pediatrics, University of Florida at Orlando Health Arnold Palmer Hospital for Children, Orlando, FL, ³Pediatrics, University of Florida, Gainesville, FL
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) with psychosis is challenging to treat with refractory cases often requiring prolonged hospitalization due to significant functional impairment and…
Abstract Number: 2782 • 2016 ACR/ARHP Annual Meeting
Bortezomib Treatment Prevents Glomerulosclerosis Associated with Lupus Nephritis in a Murine Model through Suppressive Effects on the Immune and Renin-Angiotensin Systems
Kazuhisa Nozawa¹, Yuko Matsuki², Ken Yamaji³, Naoto Tamura⁴ and Yoshinari Takasaki³, ¹2-1-1 Hongo Bunkyo-ku, Juntendo University, Tokyo, Japan, ²Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Rheumatology, Juntendo University, Tokyo, Japan
Background/Purpose: Lupus nephritis (LN) is one of the main causes of morbidity and mortality in SLE. Although a combination therapy using steroids and immunosuppressant…
Abstract Number: 1812 • 2015 ACR/ARHP Annual Meeting
The First Randomized Control Trial to Evaluate the Effectiveness of Bortezomib for Refractory Systemic Lupus Erythematosus
Tomonori Ishii¹, Yoshiya Tanaka², Atsushi Kawakami³, Kazuyoshi Saito², Kunihiro Ichinose⁴, Yuko Shirota⁵, Hiroshi Fujii⁵, Yoko Fujita⁶, Yukiko Kamogawa⁵, Tomoaki Machiyama⁵, Kanae Akita⁵ and Hideo Harigae⁵, ¹Department of Clinical Trial Implementation, Tohoku University Hospital, Clinical Research, Innovation and Education Center, Sendai, Japan, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁶Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease characterized by production and deposition of anti-dsDNA antibody. In recent years, treatment methods targeting antibody-producing B cell…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].